Related Experiment Video
Updated: Jul 21, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Angiotensin II type 1a receptor knockout ameliorates high-fat diet-induced cardiac dysfunction by regulating glucose
Abstract:
Obesity-related cardiovascular diseases are associated with overactivation of the renin-angiotensin system (RAS). However, the underlying mechanisms remain elusive. In this study, we investigate the role of angiotensin II (Ang II) in high-fat diet (HFD)-induced cardiac dysfunction by focusing on cardiac glucose and lipid metabolism and energy supply. Ang II plays a role in cardiovascular regulation mainly by stimulating angiotensin II type 1 receptor (AT1R), among which AT1aR is the most important subtype in regulating the function of the cardiovascular system. AT1aR gene knockout (AT1aR ‒/‒) rats and wild-type (WT) rats are randomly divided into four groups and fed with either a normal diet (ND) or a HFD for 12 weeks. The myocardial lipid content, Ang II level and cardiac function are then evaluated. The expressions of a number of genes involved in glucose and fatty acid oxidation and mitochondrial dynamics are measured by quantitative polymerase chain reaction and western blot analysis. Our results demonstrate that AT1aR knockout improves HFD-induced insulin resistance and dyslipidemia as well as lipid deposition and left ventricular dysfunction compared with WT rats fed a HFD. In addition, after feeding with HFD, AT1aR ‒/‒ rats not only show further improvement in glucose and fatty acid oxidation but also have a reverse effect on increased mitochondrial fission proteins. In conclusion, AT1aR deficiency ameliorates HFD-induced cardiac dysfunction by enhancing glucose and fatty acid oxidation, regulating mitochondrial dynamics-related protein changes, and further promoting cardiac energy supply.
Insights
Targeting the angiotensin II type 1a receptor (AT1aR) improves high-fat diet-induced heart problems. Blocking AT1aR enhances cardiac metabolism and mitochondrial function, offering a potential therapeutic strategy for obesity-related cardiovascular diseases.
Area of Science:
- Cardiovascular Physiology
- Metabolic Diseases
- Molecular Biology
Background:
- Obesity-related cardiovascular diseases are linked to overactive renin-angiotensin system (RAS).
- Mechanisms linking RAS overactivation to cardiac dysfunction in obesity are not fully understood.
- Angiotensin II (Ang II) primarily acts via angiotensin II type 1 receptor (AT1R), with AT1aR being crucial for cardiovascular regulation.
Purpose of the Study:
- To investigate the role of Ang II and AT1aR in high-fat diet (HFD)-induced cardiac dysfunction.
- To examine the impact of AT1aR deficiency on cardiac glucose and lipid metabolism, and energy supply in HFD-fed rats.
Main Methods:
- Utilized wild-type (WT) and AT1aR gene knockout (AT1aR ‒/‒) rats fed either a normal diet (ND) or HFD for 12 weeks.
- Assessed myocardial lipid content, Ang II levels, and cardiac function.
- Quantified gene expression related to glucose/fatty acid oxidation and mitochondrial dynamics via qPCR and Western blot.
Main Results:
- AT1aR knockout significantly improved HFD-induced insulin resistance, dyslipidemia, cardiac lipid deposition, and left ventricular dysfunction compared to WT rats.
- AT1aR ‒/‒ rats exhibited enhanced glucose and fatty acid oxidation under HFD conditions.
- AT1aR deficiency reversed the HFD-induced increase in mitochondrial fission proteins.
Conclusions:
- AT1aR deficiency ameliorates HFD-induced cardiac dysfunction.
- This protective effect is mediated by enhanced glucose and fatty acid oxidation.
- Regulation of mitochondrial dynamics and improved cardiac energy supply contribute to the observed benefits.
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension II: Pathophysiology
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure II: Pathophysiology

